Rolf Kuropka

Photo

Statement: Rolf Kuropka, CEO, Krahn Chemie Group

CHEManager asked executives and industry experts from a broad range of chemical distributors to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.